About this item:

722 Views | 122 Downloads

Author Notes:

Correspondence: G.E. Umpierrez, Emory University School of Medicine, 49 Jesse Hill Jr Dr, Atlanta, GA 30303; Tel.: +1 404 778 1665; Email: geumpie@emory.edu

Disclosures: The authors state that they have no conflict of interest.

Subject:

Research Funding:

This work was partially supported by research grants from the National Institutes of Health UL1 RR025008 (Atlanta Clinical and Translational Science Institute), American Diabetes Association 7-03-CR-35 (GEU) and Emory Egleston Children’s Research Center Seed Grant (EIF).

Keywords:

  • Diabetic ketoacidosis
  • Type 2 diabetes
  • Hyperglycemic crises
  • Ketosis-prone diabetes
  • Atypical diabetes
  • Obese

Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes?

Tools:

Journal Title:

Primary Care Diabetes

Volume:

Volume 6, Number 1

Publisher:

, Pages 61-65

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Objective Many obese children with unprovoked diabetic ketoacidosis (DKA) display clinical features of type 2 diabetes during follow up. We describe the clinical presentation, autoimmune markers and the long-term course of obese and lean children with DKA. Research design and methods We reviewed the medical records on the initial acute hospitalization and outpatient follow-up care of 21 newly diagnosed obese and 20 lean children with unprovoked DKA at Emory University affiliated children’s hospitals between 1/2003 and 12/2006. Results Obese children with DKA were older and predominantly male, had acanthosis nigricans, and had lower prevalence of autoantibodies to islet cells and glutamic acid decarboxylase than lean children. Half of the obese, but none of the lean children with DKA achieve near-normoglycemia remission and discontinued insulin therapy during follow-up. Time to achieve remission was 2.2 ± 2.3 months. There were no differences on clinical presentation between obese children who achieved near-normoglycemia remission versus those who did not. The addition of metformin to insulin therapy shortly after resolution of DKA resulted in lower hemoglobin A1c (HbA1c) levels, higher rates of near-normoglycemia remission, and lower frequency of DKA recurrence. Near-normoglycemia remission, however, was of short duration and the majority of obese patients required reinstitution of insulin treatment within 15 months of follow-up. Conclusion In contrast to lean children with DKA, many obese children with unprovoked DKA display clinical and immunologic features of type 2 diabetes during follow-up. The addition of metformin to insulin therapy shortly after resolution of DKA improves glycemic control, facilitates achieving near-normoglycemia remission and prevents DKA recurrence in obese children with DKA.

Copyright information:

© 2011 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/).

Creative Commons License

Export to EndNote